Breaking News
January 15, 2019 - AHA: New Cholesterol Guidelines Put Ethnicity in the Spotlight
January 15, 2019 - Different brain areas linked to smoking and drinking
January 15, 2019 - Henry Marsh shares insights into neurosurgery and more at Dean’s Lecture Series
January 15, 2019 - Want to Live Longer? For Just 30 Minutes a Day, Do Anything Else But Sit
January 15, 2019 - The Current issue of “The view from here” is concerned with Targets
January 15, 2019 - Plain packaging sparked tobacco price rises, new study finds
January 15, 2019 - Sedentary lifestyles can be unhealthy, physical activity can lower risk
January 15, 2019 - Gut microbiome may help prevent development of cow’s milk allergy
January 15, 2019 - Lesbian, gay and bisexual individuals more likely to suffer severe substance use disorders
January 15, 2019 - New England Journal of Medicine Publishes Positive Results of the Pivotal Trial of Cablivi (caplacizumab) for Rare Blood Clotting Disorder
January 15, 2019 - Levels of inflammatory marker (CRP) linked to housing type and tenure
January 15, 2019 - Three gifts I’m glad I gave myself in 2018
January 15, 2019 - Columbia’s Pediatrics Department Names New Vice Chairs, Expands Leadership
January 15, 2019 - US FDA Accepts Regulatory Submissions for Review of Tafamidis to Treat Transthyretin Amyloid Cardiomyopathy
January 15, 2019 - Staying fit can cut your risk of heart attack by half
January 15, 2019 - Vitamin D supplements are of no gain to those over 70, study shows
January 15, 2019 - Scientists create comprehensive new method to predict breast cancer risk
January 15, 2019 - Research shows connection between social media use and impaired risky decision-making
January 15, 2019 - FDA Approves Expanded Use of Adacel (Tdap) Vaccine for Repeat Vaccination
January 15, 2019 - Treating spinal pain with replacement discs made of ‘engineered living tissue’ moves closer to reality
January 15, 2019 - Providers Walk ‘Fine Line’ Between Informing And Scaring Immigrant Patients
January 15, 2019 - Outcomes Poorer for Medicaid Beneficiaries With STEMI
January 15, 2019 - Decorative Products on Foods Can Be Unsafe
January 15, 2019 - A dream of sustainable surgery in Uganda
January 15, 2019 - Study shows how herpes viruses and tumors have learned to manipulate the same ancient RNA
January 15, 2019 - Common Heart, Diabetes Meds May Help Ease Mental Illness
January 15, 2019 - Stress and trauma in earliest years linked to reduced hippocampal volume in adolescence
January 15, 2019 - Scientists identify endogenous activator of sigma-1 receptors in human cells
January 15, 2019 - MAR treatments unlikely to be cause of premature or low birth weight babies
January 15, 2019 - Parental CPTSD increases transmission of trauma to offspring of Tutsi genocide survivors
January 15, 2019 - High-fat diets shown to increase blood pressure
January 15, 2019 - New institute for food safety to be established in Netherlands
January 15, 2019 - Keele University researchers receive £2.4 million grant to help reduce overprescribing of opioids
January 15, 2019 - Synthetic compound reverses mutant p53 aggregate accumulation, study shows
January 15, 2019 - First elder care robot tested in a WSU smart home apartment
January 15, 2019 - Oxford researchers explore relationship between technology use and adolescent mental health
January 15, 2019 - From microbiome research to healthier and sustainable foods
January 15, 2019 - How coaching moms and dads improves infants’ language skills
January 15, 2019 - Precision health approach tapped to identify causes of poverty
January 14, 2019 - DNA origami can accurately measure how antibodies interact with several antigens
January 14, 2019 - Researchers identify multiple new subtypes of most common childhood cancer
January 14, 2019 - Total Fertility Rates Vary by State
January 14, 2019 - Elevated blood lead level in early childhood associated with increased risk of academic problems in school-aged children
January 14, 2019 - Superior technique identified that can block CRISPR gene editing
January 14, 2019 - Turning breast cancer cells into fat cells prevents the formation of metastases
January 14, 2019 - Review examines what influences HIV-positive patients to stay on antiretroviral drugs in Africa
January 14, 2019 - Identifying genetic factors that lead to squamous cell carcinoma
January 14, 2019 - Virtual video visits can replace office visits without compromising quality of care
January 14, 2019 - Health Highlights: Jan. 10, 2019
January 14, 2019 - Scientists uncover how protein clumps damage cells in Parkinson’s
January 14, 2019 - Physician-scientist’s “indomitable spirit” prevails over personal adversity
January 14, 2019 - King’s researchers receive £1.25 million to investigate fatal eating disorder
January 14, 2019 - UCR researchers uncover how plants sense temperature
January 14, 2019 - Scientists find link between colitis and colon cancer
January 14, 2019 - New skin patch provides long-acting contraceptive protection
January 14, 2019 - Asparagine synthetase deficiency – Genetics Home Reference
January 14, 2019 - Improved stem cell approach could aid fight against Parkinson’s
January 14, 2019 - New class of sleeping pill preserves ability to wake in response to danger signals
January 14, 2019 - Cancer patients are four times more likely to commit suicide
January 14, 2019 - The human brain works in reverse order to retrieve memories
January 14, 2019 - Simple tips can lead to better food choices
January 14, 2019 - Meth’s Resurgence Spotlights Lack Of Meds To Combat The Addiction
January 14, 2019 - TARA Biosystems and Insilico Medicine collaborate to discover novel therapies for cardiac disease
January 14, 2019 - Early life stress in mice affects their offspring behavior
January 14, 2019 - Depression Tied to Worse Asthma Outcomes in Urban Teens
January 14, 2019 - Santa calorie counting
January 14, 2019 - Opiod prescriptions for pet dogs misused by their masters
January 14, 2019 - People with ASD could be better at recognizing regret and relief in others finds study
January 14, 2019 - Conducting ChIP-Seq with Low Cell Numbers
January 14, 2019 - Study explores support and social networks of family carers of people with dementia
January 14, 2019 - At Risk for an Opioid OD? There’s an App for That
January 14, 2019 - Single national electronic health record will help improve care in Canadian hospitals
January 14, 2019 - Study unearths Britain’s first speech therapists
January 14, 2019 - Study reveals nuances of racial inequalities in breast cancer prevention
January 14, 2019 - Air pollution can raise the risk of miscarriage among women finds study
January 14, 2019 - An extra meal a day cuts deaths by half in elderly with hip fractures
January 14, 2019 - Researchers report vision-based neurotransmitter events for the first time
January 14, 2019 - Pharmacists could significantly reduce ED crowdedness
January 14, 2019 - PTSD linked with cardiovascular disease and cancer, study shows
January 14, 2019 - New analytic model can accurately predict patients at risk of developing PTSD
Innovative drugs and new European treatment guidelines refine, improve MS therapy

Innovative drugs and new European treatment guidelines refine, improve MS therapy

image_pdfDownload PDFimage_print

MS is the most common neurological disease in young adults. There are about 2.3 million people worldwide who face a high risk of ever worsening disabilities from this disease. This year, two innovative drugs were approved in the EU, namely, cladribine, an active agent originally used in cancer therapy, and the monoclonal antibody ocrelizumab. This marks the approval of the first drug for combating primary chronic progressive MS, a form of the disease characterized by continuously worsening symptoms from the onset. In parallel to that and at the initiative of EAN and ECTRIMS, neurologists from 13 countries drew up recommendations for MS treatment in Europe. The new treatment guideline supports physicians in weighing the opportunities and risks of the available treatment options when making therapy decisions.

There are about 2.3 million people worldwide who are suffering from multiple sclerosis (MS), the most common neurological disease in young adults. Three to four times as many women as men are affected by this chronic inflammatory disease of the central nervous system and its risk of progressive disability. “Promising new drugs and the treatment guideline published this year by the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and the European Academy of Neurology (EAN) will further refine and improve the treatment of MS in substantial ways,” EAN President Prof Günther Deuschl (Kiel, Germany) said at the occasion of the 4th Congress of the EAN in Lisbon, where broad-based discussions of the new advances in MS therapy are conducted.

For 85 to 90 percent of the patients, MS begins as a relapsing-remitting disease. But there are also patients for whom the disease takes a primary progressive course. For them, the complaints worsen continuously from the onset. Without competent treatment, a large share of the patients with relapsing-remitting MS would enter a secondary progressive phase where existing symptoms constantly worsen.

Treatment goal: maximize prevention of relapses and disability progression

Until the mid-1990s, drug therapy was only possible for acute MS relapses. With the first disease-modifying therapies such as interferons beta or glatiramer acetate, it became possible to reduce the annual relapse rate by about one third. Since then, many new drugs including monoclonal antibodies have become available which target specific immune mechanisms to be even more effective and convenient. “MS treatment today is focused on avoiding relapses to the greatest possible extent and to halt the progression of disability. However, some of these drugs may also cause dangerous side effects which have to be considered when counseling our patients,” says Prof Franz Fazekas, EAN President elect who was also involved in the development of the European MS guidelines. With competent treatment, disease control has been achieved for 80 to 85 percent of the patients by suppressing the chronic inflammatory disease of the central nervous system as effectively as possible.

Cladribine and ocrelizumab: new options expanding MS treatment

Two new drugs and forms of treatment were recently approved in the EU and should help to bring about further optimization. Cladribine was originally used in anti-cancer treatment. Its mode of action on the immune system allows administering it in a pulse like manner with long lasting effects on the lymphocytes and beyond. Patients undergoing this treatment take cladribine tablets for 14 days, followed by a one-year break in treatment. In the second year, a 14-day treatment is prescribed as therapy, finally giving way to a two-year post-observation period. While this is a convenient and exciting concept it is not yet clear in how many patients and for how long such treatment will eventually succeed to silence MS activity and what to exactly do if new relapses occur. Long-term experience will be necessary to fully appreciate the safety profile of this drug.

The second new MS therapy is the monoclonal antibody ocrelizumab, approved since the beginning of the year in the EU for treatment of active relapsing-remitting MS, but also for patients with early primary chronic progressive MS. Prof Fazekas: “There had not been any therapy for these patients before.” Ocrelizumab has a targeted effect on the B cells of the immune system, which play a part in MS.

Following an initial application, further treatment with ocrelizumab entails infusions every six months. Long-term safety data are badly awaited also in this case. Prof Fazekas: “The possibility to choose among many drugs allows neurologists to adapt MS treatment to the individual needs of their patients and along the course of their disease. MS diagnosis means that patients have to live with the condition for 60 or 70 years, so we have to help them to control MS as efficiently as possible considering both benefits and risks.”

New treatment guideline assists physicians with their choice of therapy

At the initiative of the EAN and ECTRIMS, neurologists from 13 countries drew up 21 recommendations for MS treatment. The new European treatment guideline is based on the analysis of clinical studies and supports physicians in weighing the opportunities and risks of the available treatment options when making therapy decisions. Prof Deuschl: “This new guideline is part of the EAN guideline program under which all important neurological diseases are to be reappraised. About 20 of the guidelines are currently being worked on,” Prof Deuschl added. “These efforts underscore the major significance of the EAN, which is working through overarching topics of this kind and thus providing important principles not only to medical practitioners but also for health care policy.”

Tagged with:

About author

Related Articles